Press Releases

CHG Cresilon Hemostatic Gel Logo

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology

NEW YORK — Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, announced today it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for its proprietary hemostatic gel technology. This follows Cresilon’s successful launch of VETIGEL®, its revolutionary hemostatic gel for the animal health market. …

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology Read More »

Cresilon's GMP manufacturing facility in Brooklyn, NY

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel

NEW YORK, April 8, 2021 – Cresilon, Inc., the Brooklyn-based biotechnology company, announced today the successful close of its Series A-3 financing, totaling $38.5 million. This financing is expected to allow the company to aggressively accelerate its global growth plan and expand the rollout of VETIGEL®, its revolutionary hemostatic gel for the animal health market. It …

Cresilon Closes $38.5 Million Series A-3 Financing to Accelerate Commercialization of Hemostatic Gel Read More »